
## Jeanne M Marrazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6834808/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	â€~I still desire to have a child': a qualitative analysis of intersectional HIV- and childlessness-related stigma in rural southwestern Uganda. Culture, Health and Sexuality, 2023, 25, 143-158.	1.8	1
2	Vaginal and Extra-Vaginal Bacterial Colonization and Risk for Incident Bacterial Vaginosis in a Population of Women Who Have Sex With Men. Journal of Infectious Diseases, 2022, 225, 1261-1265.	4.0	10
3	Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. Aids, 2022, 36, 257-265.	2.2	6
4	Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 2022, 74, S144-S151.	5.8	16
5	A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIVâ€negative women planning for or with pregnancy in rural Southwestern Uganda. Journal of the International AIDS Society, 2022, 25, e25894.	3.0	7
6	Bacterial Sexually Transmitted Infection Incidence Among Southern Men Who Have Sex With Men With Human Immunodeficiency Virus in the Treatment as Prevention Era, 2014–2019. Clinical Infectious Diseases, 2022, 75, 1446-1448.	5.8	1
7	PrEP service delivery preferences of black Cis-gender women living in the Southern United States. AIDS and Behavior, 2022, 26, 3469-3479.	2.7	8
8	Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Clinical Infectious Diseases, 2022, 75, 1873-1882.	5.8	10
9	What's Old Is New: the Evolution of Lymphogranuloma Venereum Proctitis in Persons Living with HIV. Current Infectious Disease Reports, 2022, 24, 97-104.	3.0	1
10	Decreasing High-risk Exposures for Healthcare Workers Through Universal Masking and Universal Severe Acute Respiratory Syndrome Coronavirus 2 Testing on Entry to a Tertiary Care Facility. Clinical Infectious Diseases, 2021, 73, e3113-e3115.	5.8	6
11	Genetic Variation in Toll-Like Receptor 5 and Colonization with Flagellated Bacterial Vaginosis-Associated Bacteria. Infection and Immunity, 2021, 89, .	2.2	3
12	Protection and Risk: Male and Female Genital Microbiota and Sexually Transmitted Infections. Journal of Infectious Diseases, 2021, 223, S222-S235.	4.0	20
13	Differences in Vaginal Microbiota, Host Transcriptome, and Proteins in Women With Bacterial Vaginosis Are Associated With Metronidazole Treatment Response. Journal of Infectious Diseases, 2021, 224, 2094-2104.	4.0	10
14	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. Current HIV/AIDS Reports, 2021, 18, 261-270.	3.1	5
15	Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa. Frontiers in Reproductive Health, 2021, 3, .	1.9	2
16	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	27.0	359
17	Molecular Characterization of Microbes in the Female Upper Genital Tract: A Valiant Quest to "Redefine―Pelvic Inflammatory Disease. Journal of Infectious Diseases, 2021, 224, S36-S38.	4.0	1
18	Screening for Chlamydia and Gonorrhea. JAMA - Journal of the American Medical Association, 2021, 326, 913.	7.4	2

#	Article	IF	CITATIONS
19	Prevalence of and Factors Associated With Genital and Extragenital Chlamydia and Gonorrhea Among Transgender Women in HIV Care in the United States, 2005 to 2016. Sexually Transmitted Diseases, 2021, 48, 410-416.	1.7	5
20	Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls. Aids, 2021, 35, 369-380.	2.2	5
21	Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living with HIV in the United States (2005-2016). Clinical Infectious Diseases, 2020, 71, 2405-2413.	5.8	7
22	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. Aids, 2020, 34, 559-567.	2.2	3
23	Sexually Transmitted Infection Prevalence Among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda. Sexually Transmitted Diseases, 2020, 47, e24-e28.	1.7	9
24	Evaluation of the National Sexually Transmitted Disease Curriculum: Reach, Utilization, and Engagement. Sexually Transmitted Diseases, 2020, 47, 412-418.	1.7	3
25	Behavioral Counseling for Sexually Transmitted Infection Risk Reduction. JAMA - Journal of the American Medical Association, 2020, 324, 640.	7.4	1
26	Cervicitis: Balancing the Goals of Empiric Therapy and Antimicrobial Stewardship to Improve Women's Health. Sexually Transmitted Diseases, 2020, 47, 387-388.	1.7	1
27	ECHO: context and limitations. Lancet, The, 2020, 395, e23.	13.7	3
28	Annals On Call - Protecting Health Care Workers From COVID-19. Annals of Internal Medicine, 2020, 172, OC1.	3.9	2
29	Annals On Call - Diagnosing SARS-CoV-2 Infection: Symptoms or No Symptoms?. Annals of Internal Medicine, 2020, 173, OC1.	3.9	0
30	High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100216.	2.6	9
31	Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. Lancet HIV,the, 2019, 6, e498-e508.	4.7	35
32	HIV Status and Other Risk Factors for Prevalent and Incident Sexually Transmitted Infection during Pregnancy (2000-2014). Infectious Diseases in Obstetrics and Gynecology, 2019, 2019, 1-8.	1.5	8
33	Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial. Journal of Infectious Diseases, 2019, 219, 1940-1947.	4.0	21
34	P239â€Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study. , 2019, , .		2
35	P728â€Correlates of syphilis in women living with and without HIV in the US women's interagency HIV study (WIHS). , 2019, , .		0
36	P588â€A multi-site comparative study to understand sources of variability in studies of the vaginal microbiota. , 2019, , .		1

#	Article	IF	CITATIONS
37	P369â€Incidence of vaginal infections in kenyan women randomized to continuous or cyclic contraceptive ring (CVR). , 2019, , .		0
38	Recent Developments in Biomedical Issues in Sexually Transmitted Infections: Implications for Behavioral Parameters of Interest. Sexually Transmitted Diseases, 2019, 46, e65-e67.	1.7	0
39	Social harms in female-initiated HIV prevention method research. Aids, 2019, 33, 2237-2244.	2.2	11
40	Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clinical Infectious Diseases, 2019, 68, 803-809.	5.8	52
41	The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. AIDS Research and Human Retroviruses, 2019, 35, 219-228.	1.1	188
42	Health Care Provider Perceptions of a Sexually Transmitted Infection Self-testing Program in an HIV Care Clinic. Sexually Transmitted Diseases, 2018, 45, 417-421.	1.7	7
43	Sexually Transmitted Infection Prevalence in Women With HIV: Is There a Role for Targeted Screening?. Sexually Transmitted Diseases, 2018, 45, 762-769.	1.7	11
44	Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. New England Journal of Medicine, 2018, 379, 1835-1845.	27.0	148
45	PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States. Journal of the Association of Nurses in AIDS Care, 2018, 29, 835-848.	1.0	48
46	Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement. PLoS Medicine, 2018, 15, e1002485.	8.4	20
47	BIOMEDICAL PREVENTION OF HIV IN WOMEN: CHALLENGES AND APPROACHES, WITH PARTICULAR REFERENCE TO THE VAGINAL MICROBIOME. Transactions of the American Clinical and Climatological Association, 2018, 129, 63-73.	0.5	7
48	Validity of self-reported history of Chlamydia trachomatisÂinfection. American Journal of Obstetrics and Gynecology, 2017, 216, 393.e1-393.e7.	1.3	12
49	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Research and Human Retroviruses, 2017, 33, 778-783.	1.1	52
50	Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. Journal of Women's Health, 2017, 26, 670-676.	3.3	5
51	Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals. Current HIV/AIDS Reports, 2017, 14, 41-46.	3.1	6
52	The fourth generation Alere TM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. Journal of Clinical Virology, 2017, 94, 15-21.	3.1	25
53	Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). Sexually Transmitted Diseases, 2017, 44, 135-140.	1.7	11
54	Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases, The, 2017, 17, e235-e279.	9.1	510

4

#	Article	IF	CITATIONS
55	Management of Gonorrhea. , 2017, , 592-596.e1.		о
56	Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities. Journal of Infectious Diseases, 2017, 216, S606-S610.	4.0	21
57	STIs Among Women Who Have Sex with Women. , 2017, , 233-246.		4
58	HIV Prevention: Opportunities and Challenges. Topics in Antiviral Medicine, 2017, 24, 123-126.	0.1	7
59	Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTNâ€003 (VOICE) study. Journal of the International AIDS Society, 2016, 19, 20642.	3.0	45
60	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 287-294.	2.1	42
61	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. Medical Clinics of North America, 2016, 100, 927-950.	2.5	11
62	Ocular Syphilis: a Clinical Review. Current Infectious Disease Reports, 2016, 18, 36.	3.0	35
63	More Easily Cultivated Than Identified: Classical Isolation With Molecular Identification of Vaginal Bacteria. Journal of Infectious Diseases, 2016, 214, S21-S28.	4.0	30
64	The Vaginal Microbiome: Current Understanding and Future Directions. Journal of Infectious Diseases, 2016, 214, S36-S41.	4.0	102
65	Variations in Clinical Presentation of Ocular Syphilis: Case Series Reported From a Growing Epidemic in the United States. Sexually Transmitted Diseases, 2016, 43, 519-523.	1.7	21
66	Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?. AIDS and Behavior, 2016, 20, 2654-2661.	2.7	14
67	An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 333-343.	2.1	123
68	Rapid Diagnosis of Trichomonas vaginalis by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay. Sexually Transmitted Diseases, 2016, 43, 369-373.	1.7	25
69	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e26-e31.	2.1	42
70	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. Journal of Infectious Diseases, 2016, 213, 335-342.	4.0	40
71	Advancing Care for Lesbian, Gay, Bisexual, and Transgender Persons: Enough Already?. Annals of Internal Medicine, 2015, 163, 143-144.	3.9	2
72	Tenofovir-Based Preexposure Prophylaxis for HIV Infection Among African Women. Obstetrical and Gynecological Survey, 2015, 70, 444-446.	0.4	8

#	Article	lF	CITATIONS
73	Levels of Genital Tract Defensins and Cytokines Differ between <scp>HIV</scp> â€Uninfected <scp>US</scp> and African Women. American Journal of Reproductive Immunology, 2015, 74, 313-322.	1.2	6
74	Relationship of Specific Bacteria in the Cervical and Vaginal Microbiotas With Cervicitis. Sexually Transmitted Diseases, 2015, 42, 475-481.	1.7	33
75	Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 212-217.	2.1	34
76	Barriers to Bacterial Sexually Transmitted Infection Testing of HIV-Infected Men Who Have Sex With Men Engaged in HIV Primary Care. Sexually Transmitted Diseases, 2015, 42, 590-594.	1.7	75
77	Disclosure of pharmacokinetic drug results to understand nonadherence. Aids, 2015, 29, 2161-2171.	2.2	71
78	Women Who Have Sex with Women Living in Low- and Middle-Income Countries: A Systematic Review of Sexual Health and Risk Behaviors. LGBT Health, 2015, 2, 91-104.	3.4	28
79	Soluble Immune Mediators and Vaginal Bacteria Impact InnateÂGenital Mucosal Antimicrobial Activity in Young Women. American Journal of Reproductive Immunology, 2015, 74, 323-332.	1.2	14
80	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sexually Transmitted Diseases, 2015, 42, 376-381.	1.7	22
81	Neisseria gonorrhoeae (Gonorrhea). , 2015, , 2446-2462.e3.		8
82	Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. Journal of Infectious Diseases, 2015, 212, 1949-1956.	4.0	13
83	Metabolic Signatures of Bacterial Vaginosis. MBio, 2015, 6, .	4.1	230
84	Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS and Behavior, 2015, 19, 770-783.	2.7	12
85	Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis. Journal of Infectious Diseases, 2015, 212, 793-802.	4.0	94
86	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 2015, 372, 509-518.	27.0	1,094
87	Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV,the, 2015, 2, e279-e287.	4.7	43
88	Factors associated with bone mineral density in healthy African women. Archives of Osteoporosis, 2015, 10, 206.	2.4	14
89	A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Research and Human Retroviruses, 2015, 31, 1055-1059.	1.1	3
90	Syphilis? An Unusual Cause of Surgical Emergency in a Human Immunodeficiency Virus-Infected Man. Open Forum Infectious Diseases, 2015, 2, ofv094.	0.9	1

1

#	Article	IF	CITATIONS
91	Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 65-73.	2.1	23
92	Addressing Standards of Care in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, S10-S14.	2.1	8
93	Improving HIV/STD Prevention in the Care of Persons Living with HIV Through a National Training Program. AIDS Patient Care and STDs, 2014, 28, 15-21.	2.5	8
94	Development of a Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. AIDS Research and Human Retroviruses, 2014, 30, A214-A214.	1.1	3
95	Bacterial Vaginosis and the Cervicovaginal Immune Response. American Journal of Reproductive Immunology, 2014, 71, 555-563.	1.2	146
96	Association of Tenofovir (TFV) Detection with Reduced Risk of Herpes Simplex virus Type-2 (HSV-2) Acquisition in the VOICE (MTN 003) Study. AIDS Research and Human Retroviruses, 2014, 30, A31-A31.	1.1	11
97	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	7.4	109
98	Uptake of HBV Vaccination and Incident HBV Infection in Women of Reproductive Age and at Risk of HIV-1 Infection in the VOICE (MTN 003) Study. AIDS Research and Human Retroviruses, 2014, 30, A278-A278.	1.1	0
99	Review: Self-collected samples are less accurate for HPV testing than clinician-collected samples. Annals of Internal Medicine, 2014, 161, JC11.	3.9	0
100	Recent advances in understanding and managing Chlamydia trachomatis infections. F1000prime Reports, 2014, 6, 120.	5.9	19
101	What's new in sexually transmitted infections in the HIV care setting: focus on syphilis and gonorrhea. Topics in Antiviral Medicine, 2014, 22, 698-701.	0.1	3
102	Sexually Transmitted Infections. Infectious Disease Clinics of North America, 2013, 27, ix-x.	5.1	0
103	Vaginal Biofilms and Bacterial Vaginosis: Of Mice and Women. Journal of Infectious Diseases, 2013, 207, 1481-1483.	4.0	14
104	Introduction to the special issue highlighting Anaerobe 2012. Anaerobe, 2013, 24, 85-86.	2.1	0
105	Screening and Management of Genital Chlamydial Infections. Infectious Disease Clinics of North America, 2013, 27, 739-753.	5.1	4
106	Bacterial Vaginosis–Associated Bacteria in Men. Sexually Transmitted Diseases, 2013, 40, 944-949.	1.7	56
107	Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention. , 2013, , 213-227.		0

108 Bacterial Vaginosis. , 2013, , 463-498.

#	Article	IF	CITATIONS
109	Editorial Commentary: Sexual Networks, Sex Hormones, and Recurrent Bacterial Vaginosis: Not Such Strange Bedfellows. Clinical Infectious Diseases, 2013, 56, 787-789.	5.8	3
110	American Sexually Transmitted Diseases Association and the Thomas Parran Award. Sexually Transmitted Diseases, 2013, 40, 275-276.	1.7	3
111	A Prospective Cohort Study Comparing the Effect of Single-Dose 2 g Metronidazole on Trichomonas vaginalis Infection in HIV-Seropositive Versus HIV-Seronegative Women. Sexually Transmitted Diseases, 2013, 40, 499-505.	1.7	26
112	More Than Meets the Eye: Associations of Vaginal Bacteria with Gram Stain Morphotypes Using Molecular Phylogenetic Analysis. PLoS ONE, 2013, 8, e78633.	2.5	67
113	Syphilis in Women. , 2013, , 461-471.		Ο
114	Chlamydia trachomatisInfection among Sexual Minorities. Issues in Infectious Diseases, 2013, , 142-150.	0.1	0
115	Enhancing Women's Sexual Health: Prevention Measures in Diverse Populations of Women. , 2013, , 197-219.		1
116	Mucosal Escherichia coli Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial. Journal of Infectious Diseases, 2012, 206, 1931-1935.	4.0	21
117	Extravaginal Reservoirs of Vaginal Bacteria as Risk Factors for Incident Bacterial Vaginosis. Journal of Infectious Diseases, 2012, 205, 1580-1588.	4.0	96
118	Bacterial Communities in Women with Bacterial Vaginosis: High Resolution Phylogenetic Analyses Reveal Relationships of Microbiota to Clinical Criteria. PLoS ONE, 2012, 7, e37818.	2.5	545
119	Behavioral Predictors of Colonization with <i>Lactobacillus crispatus</i> or <i>Lactobacillus jensenii</i> after Treatment for Bacterial Vaginosis: A Cohort Study. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-6.	1.5	34
120	The Posttrial Effect of Oral Periodic Presumptive Treatment for Vaginal Infections on the Incidence of Bacterial Vaginosis and Lactobacillus Colonization. Sexually Transmitted Diseases, 2012, 39, 361-365.	1.7	17
121	Chlamydia Positivity in Women Screened in Family Planning Clinics: Racial/Ethnic Differences and Trends in the Northwest U.S., 1997–2006. Public Health Reports, 2012, 127, 38-51.	2.5	18
122	Emerging Sexual Health Issues Among Women Who Have Sex with Women. Current Infectious Disease Reports, 2012, 14, 204-211.	3.0	51
123	Introduction to Sexually Transmitted Infections. , 2012, , 300-302.		Ο
124	<i>Chlamydia trachomatis</i> Infection Among Women Reporting Sexual Activity With Women Screened in Family Planning Clinics in the Pacific Northwest, 1997 to 2005. American Journal of Public Health, 2011, 101, 1284-1290.	2.7	61
125	Interpreting the epidemiology and natural history of bacterial vaginosis: Are we still confused?. Anaerobe, 2011, 17, 186-190.	2.1	93
126	Effect of Sexual Activity on Vaginal Colonization With Hydrogen Peroxide-Producing Lactobacilli and Gardnerella vaginalis. Sexually Transmitted Diseases, 2011, 38, 1137-1144.	1.7	34

#	Article	IF	CITATIONS
127	Sexually Transmitted Infections Among Women Who Have Sex With Women. Clinical Infectious Diseases, 2011, 53, S84-S91.	5.8	60
128	Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases, 2011, 53, S64-S78.	5.8	40
129	A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sexually Transmitted Infections, 2011, 87, 399-405.	1.9	31
130	Establishing and Sustaining a Healthy Vaginal Environment: Analysis of Data From a Randomized Trial of Periodic Presumptive Treatment for Vaginal Infections. Journal of Infectious Diseases, 2011, 204, 323-326.	4.0	11
131	Performance of Swabs, Lavage, and Diluents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators. PLoS ONE, 2011, 6, e23136.	2.5	77
132	Temporal Variability of Human Vaginal Bacteria and Relationship with Bacterial Vaginosis. PLoS ONE, 2010, 5, e10197.	2.5	363
133	Risks for Acquisition of Bacterial Vaginosis Among Women Who Report Sex with Women: A Cohort Study. PLoS ONE, 2010, 5, e11139.	2.5	82
134	Antiretroviral-based HIV prevention strategies for women. Expert Review of Anti-Infective Therapy, 2010, 8, 1177-1186.	4.4	9
135	Neisseria gonorrhoeae. , 2010, , 2753-2770.		9
136	Prevalence and Risks for Bacterial Vaginosis in Women Who Have Sex With Women. Sexually Transmitted Diseases, 2010, 37, 335-339.	1.7	62
137	Walter E. Stamm, MD, 1945–2009. Sexually Transmitted Diseases, 2010, 37, 281-282.	1.7	0
138	Even NHANES Evolves: Some Surprising Findings About Women Who Have Sex With Women. Sexually Transmitted Diseases, 2010, 37, 414-415.	1.7	2
139	Prevalence and risks for bacterial vaginosis in women who have sex with women. Sexually Transmitted Diseases, 2010, 37, 335-9.	1.7	49
140	Preferred Characteristics of Vaginal Microbicides in Women with Bacterial Vaginosis. Journal of Women's Health, 2009, 18, 1163-1167.	3.3	6
141	Changes in Vaginal Bacterial Concentrations with Intravaginal Metronidazole Therapy for Bacterial Vaginosis as Assessed by Quantitative PCR. Journal of Clinical Microbiology, 2009, 47, 721-726.	3.9	141
142	Distribution of Genital <i>Lactobacillus</i> Strains Shared by Female Sex Partners. Journal of Infectious Diseases, 2009, 199, 680-683.	4.0	71
143	Diversity of Human Vaginal Bacterial Communities and Associations with Clinically Defined Bacterial Vaginosis. Applied and Environmental Microbiology, 2008, 74, 4898-4909.	3.1	230
144	Chlamydia Positivity in American Indian/Alaska Native Women Screened in Family Planning Clinics, 1997–2004. Sexually Transmitted Diseases, 2008, 35, 753-757.	1.7	11

#	Article	IF	CITATIONS
145	Routine HIV testing in the context of syndromic management of sexually transmitted infections: outcomes of the first phase of a training programme in Botswana. Sexually Transmitted Infections, 2008, 84, 259-264.	1.9	9
146	Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sexually Transmitted Infections, 2008, 84, 57-61.	1.9	32
147	Acceptability of Urine-Based Screening for Chlamydia trachomatis in Asymptomatic Young Men: A Systematic Review. Sexually Transmitted Diseases, 2008, 35, S28-S33.	1.7	31
148	The Cost-Effectiveness of Screening Men for Chlamydia trachomatis: A Review of the Literature. Sexually Transmitted Diseases, 2008, 35, S51-S60.	1.7	35
149	Relationship of Specific Vaginal Bacteria and Bacterial Vaginosis Treatment Failure in Women Who Have Sex with Women. Annals of Internal Medicine, 2008, 149, 20.	3.9	146
150	Elusive aetiology of bacterial vaginosis. Do lesbians have a clue?. Sexually Transmitted Infections, 2007, 83, 424-425.	1.9	2
151	Expanding the Spectrum of Pathogens in Urethritis: Implications for Presumptive Therapy?. Clinical Infectious Diseases, 2007, 45, 872-874.	5.8	6
152	Superficial Hepatic Capsular Lesions in a Systemically Ill Young Woman. Sexually Transmitted Diseases, 2007, 34, 139-140.	1.7	0
153	Effectiveness of Two Tinidazole Regimens in Treatment of Bacterial Vaginosis. Obstetrics and Gynecology, 2007, 110, 302-309.	2.4	46
154	Selective Testing Criteria for Gonorrhea among Young Women Screened for Chlamydial Infection: Contribution of Race and Geographic Prevalence. Journal of Infectious Diseases, 2007, 196, 731-737.	4.0	14
155	Within the Hidden Epidemic: Sexually Transmitted Diseases and HIV/AIDS Among American Indians and Alaska Natives. Sexually Transmitted Diseases, 2007, 34, 767-777.	1.7	46
156	Population-Based Outreach for Chlamydia Screening in Men: Results From a Randomized Trial. Sexually Transmitted Diseases, 2007, 34, 837-839.	1.7	27
157	Acceptability of Urine-Based Screening for Chlamydia trachomatis to Asymptomatic Young Men and Their Providers. Sexually Transmitted Diseases, 2007, 34, 147-153.	1.7	15
158	Management of Women with Cervicitis. Clinical Infectious Diseases, 2007, 44, S102-S110.	5.8	83
159	Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis. Journal of Clinical Microbiology, 2007, 45, 3270-3276.	3.9	328
160	Emerging issues in management of sexually transmitted diseases in HIV infection. Current Infectious Disease Reports, 2007, 9, 518-30.	3.0	4
161	Chlamydial Infections Among Female Adolescents Screened in Juvenile Detention Centers in Washington State, 1998???2002. Sexually Transmitted Diseases, 2006, 33, 63-67.	1.7	34
162	Bacteria Associated with Bacterial Vaginosis. New England Journal of Medicine, 2006, 354, 202-203.	27.0	17

#	Article	IF	CITATIONS
163	Reply to Forney et al Journal of Infectious Diseases, 2006, 194, 1469-1470.	4.0	11
164	Risk Factors for Cervicitis among Women with Bacterial Vaginosis. Journal of Infectious Diseases, 2006, 193, 617-624.	4.0	63
165	A Persistent(ly) Enigmatic Ecological Mystery: Bacterial Vaginosis. Journal of Infectious Diseases, 2006, 193, 1475-1477.	4.0	40
166	Women's Satisfaction with an IntravaginalLactobacillusCapsule for the Treatment of Bacterial Vaginosis. Journal of Women's Health, 2006, 15, 1053-1060.	3.3	29
167	Dangerous Assumptions: Lesbians and Sexual Death. Sexually Transmitted Diseases, 2005, 32, 570-571.	1.7	20
168	Molecular methodology in determining vaginal flora in health and disease: Its time has come. Current Infectious Disease Reports, 2005, 7, 463-470.	3.0	58
169	Impact of Patient Characteristics on Performance of Nucleic Acid Amplification Tests and DNA Probe for Detection of Chlamydia trachomatis in Women with Genital Infections. Journal of Clinical Microbiology, 2005, 43, 577-584.	3.9	26
170	Cervical Specimen Order and Performance Measures of Chlamydia trachomatis Diagnostic Testing. Journal of Clinical Microbiology, 2005, 43, 5295-5297.	3.9	6
171	Sexual tourism: implications for travelers and the destination culture. Infectious Disease Clinics of North America, 2005, 19, 103-120.	5.1	15
172	Molecular Identification of Bacteria Associated with Bacterial Vaginosis. New England Journal of Medicine, 2005, 353, 1899-1911.	27.0	1,080
173	Mucopurulent Cervicitis: No Longer Ignored, but Still Misunderstood. Infectious Disease Clinics of North America, 2005, 19, 333-349.	5.1	38
174	Sexual Practices, Risk Perception and Knowledge of Sexually Transmitted Disease Risk Among Lesbian and Bisexual Women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3.3	117
175	Sexual Practices, Risk Perception and Knowledge of Sexually Transmitted Disease Risk Among Lesbian and Bisexual Women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3.3	7
176	Sexual practices, risk perception and knowledge of sexually transmitted disease risk among lesbian and bisexual women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3.3	72
177	Barriers to Infectious Disease Care among Lesbians1. Emerging Infectious Diseases, 2004, 10, 1975-1978.	4.3	66
178	Re-evaluating Selective Screening Criteria for Chlamydial Infection Among Women in the U.S. Pacific Northwest. Sexually Transmitted Diseases, 2004, 31, 283-289.	1.7	28
179	Lesbian Health Matters: A Pap Test Education Campaign Nearly Thwarted by Discrimination. Health Promotion Practice, 2004, 5, 314-325.	1.6	15
180	Reproductive health history of lesbians: implications for care. American Journal of Obstetrics and Gynecology, 2004, 190, 1298-1304.	1.3	46

#	Article	IF	CITATIONS
181	Evolving issues in understanding and treating bacterial vaginosis. Expert Review of Anti-Infective Therapy, 2004, 2, 913-922.	4.4	27
182	Chlamydia trachomatis infection in asymptomatic men. American Journal of Preventive Medicine, 2003, 24, 36-42.	3.0	44
183	Functional Characterization of Class Ia- and Non-Class Ia-Restricted <i>Chlamydia</i> -Reactive CD8+ T Cell Responses in Humans. Journal of Immunology, 2003, 171, 4278-4286.	0.8	24
184	Prevalence and Risk Factors for Infection With Herpes Simplex Virus Type-1 and -2 Among Lesbians. Sexually Transmitted Diseases, 2003, 30, 890-895.	1.7	59
185	Title is missing!. Obstetrical and Gynecological Survey, 2003, 58, 351-358.	0.4	7
186	The Clinical and Economic Consequences of Screening Young Men for Genital Chlamydial Infection. Sexually Transmitted Diseases, 2003, 30, 99-106.	1.7	36
187	Common Complementary and Alternative Therapies for Yeast Vaginitis and Bacterial Vaginosis: A Systematic Review. Obstetrical and Gynecological Survey, 2003, 58, 351-358.	0.4	47
188	Head-to-Head Multicenter Comparison of DNA Probe and Nucleic Acid Amplification Tests for Chlamydia trachomatis Infection in Women Performed with an Improved Reference Standard. Journal of Clinical Microbiology, 2002, 40, 3757-3763.	3.9	111
189	Extracts from "Concise Clinical Evidence": Vulvovaginal candidiasis. BMJ: British Medical Journal, 2002, 325, 586-586.	2.3	8
190	Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstetrics and Gynecology, 2002, 100, 579-584.	2.4	48
191	Characterization of Vaginal Flora and Bacterial Vaginosis in Women Who Have Sex with Women. Journal of Infectious Diseases, 2002, 185, 1307-1313.	4.0	234
192	Urine-Based Screening for Chlamydia trachomatis in Men Attending Sexually Transmitted Disease Clinics. Sexually Transmitted Diseases, 2001, 28, 219-225.	1.7	47
193	Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour. International Journal of STD and AIDS, 2001, 12, 41-46.	1.1	48
194	Impact of new sexually transmitted disease diagnostics on clinical practice and public health policy. Current Infectious Disease Reports, 2001, 3, 147-151.	3.0	5
195	Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour. International Journal of STD and AIDS, 2001, 12, 41-46.	1.1	24
196	Genital human papillomavirus infection in women who have sex with women: A review. American Journal of Obstetrics and Gynecology, 2000, 183, 770-774.	1.3	108
197	Genital Human Papillomavirus Infection in Women Who Have Sex with Women: A Concern for Patients and Providers. AIDS Patient Care and STDs, 2000, 14, 447-451.	2.5	32
198	Sexually transmitted infections in women who have sex with women: who cares?. Sexually Transmitted Infections, 2000, 76, 330-332.	1.9	26

#	Article	IF	CITATIONS
199	Genital Human Papillomavirus Infection in Women Who Have Sex with Women. Journal of Infectious Diseases, 1998, 178, 1604-1609.	4.0	144
200	Performance and Cost-Effectiveness of Selective Screening Criteria for Chlamydia trachomatis Infection in Women. Sexually Transmitted Diseases, 1997, 24, 131-141.	1.7	176
201	Community-Based Urine Screening for Chlamydia trachomatis with a Ligase Chain Reaction Assay. Annals of Internal Medicine, 1997, 127, 796.	3.9	123
202	Selective Screening for Chlamydial Infection In Women: A Comparison of Three Sets of Criteria. Family Planning Perspectives, 1997, 29, 158.	0.7	36
203	Cesarean delivery in women with genital herpes in Washington state, 1989-1991. Infectious Diseases in Obstetrics and Gynecology, 1997, 5, 29-35.	1.5	4
204	Population-level correlation between incidence of curable sexually transmitted infections and HIV-1 among African women participating in HIV-1 pre-exposure prophylaxis trials. Journal of Infectious Diseases, 0, , .	4.0	0